LLY Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$796.03 |
| 52 Week High | US$972.53 |
| 52 Week Low | US$561.65 |
| Beta | 0.40 |
| 1 Month Change | -4.37% |
| 3 Month Change | -14.86% |
| 1 Year Change | 33.23% |
| 3 Year Change | 189.17% |
| 5 Year Change | 514.79% |
| Change since IPO | 28,242.65% |
Recent News & Updates
Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Dec 04Here's Why Eli Lilly (NYSE:LLY) Can Manage Its Debt Responsibly
Nov 29
Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Nov 28Recent updates
Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Dec 04Here's Why Eli Lilly (NYSE:LLY) Can Manage Its Debt Responsibly
Nov 29Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Nov 28Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
Nov 21Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next
Nov 01Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges
Oct 30Eli Lilly Buy On Weakness Signal (Technical Analysis)
Oct 20Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Sep 30Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Sep 20Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth
Sep 18Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside
Sep 04Eli Lilly: Tirzepatide's Winning Streak Continues
Aug 20Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)
Aug 12Shareholder Returns
| LLY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.1% | -2.6% | -0.2% |
| 1Y | 33.2% | 9.3% | 28.8% |
Return vs Industry: LLY exceeded the US Pharmaceuticals industry which returned 9.3% over the past year.
Return vs Market: LLY exceeded the US Market which returned 28.8% over the past year.
Price Volatility
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LLY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LLY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| LLY fundamental statistics | |
|---|---|
| Market cap | US$719.97b |
| Earnings (TTM) | US$8.37b |
| Revenue (TTM) | US$40.86b |
85.6x
P/E Ratio17.5x
P/S RatioIs LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLY income statement (TTM) | |
|---|---|
| Revenue | US$40.86b |
| Cost of Revenue | US$7.80b |
| Gross Profit | US$33.06b |
| Other Expenses | US$24.69b |
| Earnings | US$8.37b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 9.30 |
| Gross Margin | 80.91% |
| Net Profit Margin | 20.48% |
| Debt/Equity Ratio | 218.1% |
How did LLY perform over the long term?
See historical performance and comparison